A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Completed · Phase 1

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.

Key facts

Study ID

NCT00886821

Run by

Pfizer

People needed

114

Starts

2008-10-01

Expected to finish

2011-06-01

Last updated by the study team

2017-04-18

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and/or female patients (females will be women of non-childbearing potential) with an historical diagnosis of type 2 diabetes mellitus, who are currently being treated with metformin at a dose at or near maximum.
• Hb A1c between 7-10%.
• Fasting C-peptide >0.4 nmol/L.

You may not qualify if…

• History of clinically significant chronic conditions other than T2DM not well controlled by either diet or medications.
• Patients with pancreatitis or considered a high risk for pancreatitis.
• History of contraindications to metformin therapy.
• Previous treatment with an approved or investigational GLP 1 mimetic.

Where it is running

• Cetero Research — Miami Gardens, Florida, United States
• Cetero Research - San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.